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Here, we demonstrate that SENP2, a desumoylating enzyme, plays a critical role in the control of adipo-
genesis. SENP2 expression was markedly increased upon the induction of adipocyte differentiation, and this
increase was dependent on protein kinase A activation. Remarkably, knockdown of SENP2 led to a dramatic
attenuation of adipogenesis with a marked decrease in PPAR and C/EBP mRNA levels. Knockdown of
SENP2 also caused a marked reduction in the level of C/EBP protein but not in that of C/EBP mRNA.
Interestingly, sumoylation of C/EBP dramatically increased its ubiquitination and destabilization, and this
increase could be reversed by SENP2. In addition, overexpression of C/EBP could overcome the inhibitory
effect of SENP2 knockdown on adipogenesis. Furthermore, SENP2 was absolutely required for adipogenesis of
preadipocytes implanted into mice. These results establish a critical role for SENP2 in the regulation of
adipogenesis by desumoylation and stabilization of C/EBP and in turn by promoting the expression of its
downstream effectors, such as PPAR and C/EBP.
A large number of transcription factors are modified by the
small ubiquitin (Ub)-related modifier (SUMO), and this cova-
lent modification regulates their transcriptional activities (12,
16, 17). Unlike ubiquitination, SUMO modification is not a
signal for protein degradation. SUMO modification regulates
the target proteins through various mechanisms such as affect-
ing cellular localization, protein-protein interaction, or stabil-
ity of the target proteins. SUMO modification (sumoylation) is
a reversible process that is catalyzed by SUMO-specific pro-
teases (SENPs) (27). Six SENPs (SENP1, -2, -3, -5, -6, and -7)
have been identified in humans, and they have different cellu-
lar localization and substrate specificities (42). Although the
biochemical properties of SENPs have been well documented,
their specific targets and physiological roles are known in a
limited number of cases. SENP1 plays a key role in the hypoxic
response by regulating HIF1 stability (6). SUSP4, a newly
identified mouse SENP, inhibits cell growth by positively reg-
ulating p53 by promoting the self-ubiquitination of Mdm2 (21).
In addition, overexpression of SENP2 is involved in the down-
regulation of -catenin, whereas the direct target of SENP2 in
this process is unknown (19). It has also been reported that
SENP5 regulates cell division and mitochondrial morphology;
however, the targets of SENP5 have not been identified (9, 46).
The adipose tissues function as a reservoir of excessive energy.
They also secrete adipokines that regulate physiological and
pathological events involving energy metabolism, insulin sensitiv-
ity, atherogenesis, and inflammatory responses. Adipocyte dif-
ferentiation from preadipocytes occurs by serial inductions of
transcription factors, and this process is tightly regulated. Ex-
pression of C/EBP and C/EBP is induced immediately after
stimulation, followed by the induction of PPAR and C/EBP
(5, 43). PPAR induces several adipocyte-specific genes, in-
cluding aP2 and adiponectin, and C/EBP acts in concert with
PPAR in this process (25, 26, 33, 34). CREB (cyclic AMP
[cAMP] response element-binding protein) is also involved in
the induction of C/EBP and PPAR (11). In addition, several
reports have shown that additional transcription factors, such
as KLF5, KLF4 and Foxo-1, are involved in adipogenesis (4,
28, 31). While C/EBP and C/EBP are expressed immediately
after treatment with differentiation inducers, expression of
their downstream genes, the PPAR and C/EBP genes, does
not begin until day 2 after treatment. It has been suggested that
mitotic clonal expansion is a prerequisite for the induction of
PPAR and C/EBP (38, 39). It has also been reported that
C/EBP proteins are phosphorylated sequentially by mitogen-
activated protein kinase (MAPK), CDK2, and GSK3 to ac-
quire their C/EBP and PPAR promoter DNA-binding ac-
tivities (22, 37), suggesting that C/EBP is a master regulator
of adipocyte differentiation.
Several transcription factors regulating adipogenesis can be
modified by SUMO. Sumoylation of C/EBP and C/EBP
negatively regulates their transcriptional activities in a tran-
sient transfection and reporter assay system (10, 36); however,
a mechanism(s) by which sumoylation regulates their transcrip-
tional activities has not been identified. PPAR is also modi-
fied by SUMO, and a PPAR mutant in which the major
sumoylation site Lys107 is replaced with Arg stimulates adipo-
genesis more efficiently than does wild-type PPAR (29, 41). In
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addition, sumoylation of KLF5 regulates lipid metabolism in-
volving PPAR (30) and SUMO-conjugating enzyme Ubc9
regulates glucose transporter 4 turnover in adipocytes (23).
These results indicate the possibility that regulation of sumoy-
lation plays a role in adipogenesis and lipid metabolism.
In the present study, we tested whether a SENP is involved
in adipogenesis. We demonstrated that SENP2 was induced in
a cAMP-dependent fashion in the early stage of adipogenesis.
SENP2 desumoylated and stabilized C/EBP, whereas knock-
down of SENP2 led to a decrease in the stability of the tran-
scription factor and, in turn, inhibition of adipogenesis. In
addition, overexpression of C/EBP could overcome the in-
hibitory effect of SENP2 knockdown on adipogenesis. Collec-
tively, our findings indicate that SENP2 plays an essential role
in the control of adipogenesis.
MATERIALS AND METHODS
Plasmids and antibodies. pFLAG-SUMO1, pMyc-SUMO1, pMyc-SENP1,
pFLAG-SENP2, and pFLAG-SENP3 were prepared as described previously (8).
Expression vectors for mouse C/EBP and CREB were obtained from J. B. Kim
(Seoul National University, Seoul, South Korea). To generate the hemagglutinin
(HA)-C/EBP expression vector, a cDNA fragment of mouse C/EBP (LAP)
was inserted into pcDNA-HA. SENP2 mutant forms in which Cys548 was re-
placed with Ser (referred to as C548S) (19) and Arg576 and Lys577 were
replaced with Leu and Met, respectively (RK576/577LM) (3), were generated by
site-directed mutagenesis (Stratagene). To generate SENP2 reporter vectors, the
promoter region of mouse SENP2 (bp 1980 to 93) was ligated to the lucif-
erase (Luc) gene in the pGL2-basic vector (Promega). Serial deletions of the
promoter with the sequences from 868 or 157 to 93 were also generated. In
the deletion construct with the 157 to 93 sequence, ACG was replaced with
GTT by site-directed mutagenesis (i.e., 103 to 96, TGACGTCA 3 TGGT
TTCA). Small interfering RNAs (siRNAs) of SENP1 and SENP2 were pur-
chased from Dharmacon. Antibodies against PPAR, C/EBP, CEBP, CEBP,
aP2, SENP2, ubiquitin, SUMO1, GAPDH, CREB, and c-Myc (9E10) were
purchased from Santa Cruz Biotechnology. Antibody against HA was obtained
from Roche, and antibodies against FLAG and -actin were purchased from
Sigma-Aldrich.
Cell culture and adipocyte differentiation. 3T3-L1 preadipocytes were ob-
tained from J. W. Kim (Yonsei University, Seoul, South Korea). They were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% calf serum (Invitrogen). Differentiation of 3T3-L1 cells was induced by
treatment with DMI [5 g/ml insulin, 0.25  dexamethasone (Dex), 0.5 mM
3-isobutyl--methylxanthine (IBMX)] in DMEM supplemented with 10% fetal
bovine serum (FBS). Two days after treatment, cells were maintained in DMEM
supplemented with 10% FBS and 1 g/ml insulin for up to 10 days with a
medium change every other day. For knockdown of SENP2 or SENP1, 3T3-L1
cells were transfected with siRNA (50 nM) using Lipofectamine 2000 (Invitro-
gen) 1 day before the addition of DMI. Lipid droplets were stained by 5% Oil
Red O in 60% isopropanol. COS-7 cells were maintained in DMEM supple-
mented with 10% FBS.
Generation of stable preadipocyte cell lines. cDNA for C/EBP (LAP) or
C/EBP K133R was inserted into pBabe-Puro. Bosc cells were transfected with
pBabe-Puro or pBabe-Puro-C/EBP. The resulting retrovirus was used to infect
3T3-L1 cells, and cells harboring pBabe-Puro, pBabe-Puro-C/EBP, or pBabe-
Puro-C/EBP K133R were then selected by puromycin treatment. To generate
stable preadipocytes (3T3-F442A) in which SENP2 expression is knocked down,
the RNAi-Ready pSIREN-RetroQ (Clontech, Mountain View, CA)-mediated
retroviral system was used. The DNA sequence used for SENP2 knockdown was
AAAGTTATTGGAGCGACT.
Animals. Animals were handled in compliance with the Guide for Experimen-
tal Animal Research from the Laboratory for Experimental Animal Research,
Clinical Research Institute, Seoul National University Hospital. C57BL/6J, ob/
ob, and db/db mice (all 11 weeks old) were used in this study. The control group
(9-week-old C57BL/6J male mice) was fed a 78% sucrose diet (Research Diet
Inc.), and the high-fat diet group was fed a 60% fat diet for 4 weeks. The body
weight and blood glucose level of the control group were 25.9 	 0.9 g and
147.0 	 13.9 mg/dl, and those of the high-fat diet group were 31.0 	 1.5 g and
213.6 	 11.2 mg/dl, respectively.
RNA preparation, Northern blot analysis, and real-time PCR. Aliquots (5 to
10 g) of total RNAs prepared with Trizol (Invitrogen) were electrophoresed in
1% agarose-formaldehyde gels and transferred to Nytran membranes (Schlei-
cher & Schuell). Membranes were hybridized with -32P-labeled probes in Ex-
pressHyb solution (BD Stratagene) and then autoradiographed. Probes were
prepared by PCR using primers 5
-ACTACGGTTACGTGAGCCTCGG-3
 and
5
-GCTGCTTGAACAAGTTCCGCAG-3
 for mouse C/EBP, 5
-TCGACTTC
AGCGCCTACATTGAC-3
 and 5
-ACAACTCCACCAGCTTCTGCTG-3
 for
mouse C/EBP, 5
-CAATGCCCCGCCTGGTCTTCTA-3
 and 5
-GCACTCCA
GCATTAGAGAAGCTAGC-3
 for mouse SENP2, and 5
-GAGGATTCGGC
AGCGGTCTTAGG-3
 and 5
-ACAGCTGGAGCCTGGGTCCTCTG-3
 for
mouse RPS2. For real-time PCR, TaqMan Master Mix reagents and a TaqMan
ABI PRISM 7000 sequence detector system (Applied Biosystems) were used.
Primers and probes were purchased from Applied Biosystems. 18S rRNA was
used as an endogenous control. Analysis was performed in triplicate and re-
peated at least three times.
Transient transfection of plasmids and Luc reporter assay. 3T3-L1 cells were
plated in 12-well plates and transfected with 300 ng of Luc reporter vectors
carrying serial deletions of the SENP2 promoter region and 200 ng of pCMV-
gal. Cells were treated with forskolin (10 M) for 18 h and then harvested. The
Luc reporter assay was performed in accordance with the manufacturer’s instruc-
tions (Invitrogen). For the C/EBP transcriptional activity assay, COS-7 cells
were transfected with a p21 promoter-Luc reporter vector (1458 p21-Luc) (200
ng) (32) and expression vectors for C/EBP (20 ng), SENP2 (20, 50, 100 ng), or
SENP2 C548S (100 ng) and pCMV-gal (100 ng).
EMSA. To prepare nuclear extracts, cells were lysed in 10 mM HEPES (pH
7.9)–1.5 mM MgCl2–10 mM KCl–0.5 mM dithiothreitol (DTT). After centrifu-
gation at 3,300  g, nuclei were suspended in 20 mM HEPES (pH 7.9)–1.5 mM
MgCl2–0.42 M NaCl–25% (vol/vol) glycerol–0.2 mM EDTA–0.5 mM phenyl-
methylsulfonyl fluoride (PMSF)–0.5 mM DTT. They were then dialyzed in 20
mM HEPES (pH 7.9)–100 mM KCl–20% glycerol–0.2 mM EDTA–0.5 mM
PMSF–0.5 mM DTT. To determine CREB binding to the SENP2 promoter by
electrophoretic mobility shift assay (EMSA), an -32P-labeled oligonucleotide
probe with the bp 113 to 81 sequence (5
-CGGAAGAAGGTGACGTCAA
CGGCTTCTAGAGA-3
) of the promoter was incubated with nuclear extracts
(2 g) in 10 mM HEPES (pH 7.9)–50 mM KCl–0.1 mM EDTA–0.25 mM
DTT–0.1 mg/ml poly(dI-dC)–0.01% Nonidet P-40–10% glycerol for 10 min.
Competition assays were performed by supplementing increasing amounts of
unlabeled wild-type or mutated probes. Supershift assays were carried out by
incubation of nuclear extracts with anti-CREB antibody for 15 min before ad-
dition of the labeled probe. For the EMSA of C/EBP binding, the C/EBP
binding site of the C/EBP promoter, 5
-ttGCAGTTGCGCCACGATC-3

(191 to 172), was used as the probe (38). After incubation, the samples were
subjected to electrophoresis on 5% gels under nondenaturing conditions, fol-
lowed by autoradiography.
ChIP. For chromatin immunoprecipitation (ChIP), 3T3-L1 cells were incu-
bated with DMI or IBMX for 8 h. After incubation, cells were treated with 1%
formaldehyde for 10 min, harvested, and resuspended in 100 mM Tris-HCl (pH
9.4)–10 mM DTT–protease inhibitors. Nuclei were isolated by centrifugation and
resuspended in 10 mM Tris-HCl (pH 8.0)–1 mM EDTA–0.5 mM EGTA–1 mM
DTT–protease inhibitors. After sonication, nuclear extracts were incubated with
anti-CREB antibody, salmon sperm DNA, and protein G-Sepharose in radio-
immunoprecipitation assay buffer overnight. Precipitates were resolved in 1%
sodium dodecyl sulfate (SDS)–0.1 M NaHCO3 and incubated with 200 mM
NaCl. DNA was purified and subjected to PCR using primers 5
-CCTGTTGC
TAGGCTTACAAGGAGC-3
 (bp 186) and 5
-CTTCAGCCGTAGCCAGG
ATCAG-3
 (bp 4) of the SENP2 promoter.
Immunoprecipitation and immunoblot analysis. COS-7 cells plated on 60-mm
dishes were transfected with 0.25 g of pHA-C/EBP, 1 g of pFLAG-SUMO1,
1 g of pMyc-ubiquitin, and 0.25, 0.5, or 1 g of SENP expression vectors by
using Lipofectamine plus (Invitrogen). After incubation for 24 h, cells were lysed
in 20 mM HEPES (pH 7.4)–150 mM NaCl–1% Triton X-100–1% sodium de-
oxycholate–1% SDS–1 mM EDTA. Cell lysates (1 mg) were incubated with 2 g
of anti-HA antibody for 4 h at 4°C and then with protein A-Sepharose for the
next 1 h. Precipitates were subjected to SDS-polyacrylamide gel electrophoresis,
followed by immunoblot analysis. Lysates of 3T3-L1 cells were also subjected to
immunoprecipitation with anti-C/EBP or anti-SUMO antibody.
Implantation of 3T3-F442A preadipocytes and examination of fat pads. 3T3-
F442A preadipocytes were grown to 90% confluence and transfected with siNS
or siSENP2 (50 nM) for 4 h. Cells were trypsinized and then suspended in
DMEM with 10% calf serum. After centrifugation, cell pellets were resuspended
in DMEM with 10% calf serum. Cells (3  107 cells) were injected into the
subcutis of the abdomens of 9-week-old BALB/c nude mice (CAnN.Cg-Foxn1-
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nu/CrljBgi athymic mice; Orient Bio, Inc., Gyeonggi-Do, South Korea) (24). Fat
pads generated from the implanted cells were removed, fixed in buffered forma-
lin, and stained with hematoxylin and eosin (H&E) or subjected to immunohis-
tochemistry with antiperilipin antibody (Research Diagnostics, Concord, MA)
and detected with an LSM 710 confocal microscope (Carl Zeiss, Jena, Germany)
5 weeks after implantation.
Statistical analysis. Statistical analysis was performed using SPSS version 12.0
(SPSS Inc., Chicago, IL). Statistical significance was tested using the Mann-
Whitney U test. A P value of 0.05 was considered statistically significant.
RESULTS
Expression of SENP2 mRNA is induced at the early stage of
adipogenesis. To test whether SENP activity is involved in
adipogenesis, the changes in SENP1 and SENP2 mRNA levels
during adipogenesis of 3T3-L1 cells were monitored. Neither
the SENP1 nor the SENP2 mRNA level was substantially
changed at 24 or 48 h after treatment with the adipocyte
differentiation inducers Dex, IBMX, and insulin (henceforth
referred to as DMI) (Fig. 1A). When monitoring the SENP1
and SENP2 mRNA levels at the very early stage of differen-
tiation, we found that the SENP2 mRNA level markedly in-
creased within 4 h after the induction of adipocyte differenti-
ation (Fig. 1B). The SENP1 mRNA level, unlike the SENP2
mRNA level, was not induced. In accord with a previous report
(5), the transcript levels of C/EBP and C/EBP were also dra-
matically increased within 1 to 2 h after treatment with DMI and
gradually declined thereafter, indicating that the increased ex-
pression of C/EBP and C/EBP precedes that of SENP2 mRNA
(Fig. 1B, right panel). Consistent with the induction of the
C/EBP and SENP2 mRNA levels, the C/EBP protein level was
rapidly increased by DMI and the SENP2 protein level was grad-
ually increased within 24 h (Fig. 1C). These results implicate
SENP2 in adipogenesis.
SENP2 mRNA expression is induced by PKA activation.
Since DMI consists of Dex, IBMX, and insulin, we examined
whether an individual component by itself could affect the
expression of SENP2 mRNA. IBMX dramatically increased
the SENP2 mRNA level, unlike insulin and Dex, which had
relatively little or no effect (Fig. 1D). Since IBMX is known to
elevate the intracellular cAMP level, we tested whether the
increase in the SENP2 mRNA level was mediated by cAMP-
dependent activation of protein kinase A (PKA). H89, a PKA
inhibitor, diminished the IBMX-mediated increase in the
SENP2 mRNA level (Fig. 1E). On the other hand, forskolin, a
PKA activator, alone could increase the SENP2 mRNA level
(Fig. 1F). These results suggest that activation of PKA is re-
sponsible for the induction of SENP2 mRNA expression.
The SENP2 promoter has a functional CRE. Activated PKA
phosphorylates CREB, which in turn binds to cis-acting cAMP
response elements (CRE) in the promoters and stimulates the
expression of the target genes (13). To identify a functional
CRE, we generated a serial deletion of the SENP2 promoter
region (Fig. 2A, upper panel). Transient transfection into
3T3-L1 preadipocytes and reporter assays reveal that deletion
of the sequence from bp 1980 to bp 868 or 157 has little
effect on the forskolin-mediated increase in Luc activity (Fig.
2A, lower panel), indicating that a CRE is located downstream
of bp 157 of the promoter. Since a sequence similar to a
consensus CRE is located at bp 103 to 96 from the tran-
FIG. 1. Expression of SENP2 mRNA during adipogenesis. (A) 3T3-L1 cells were incubated with DMI for induction of adipogenesis. Total
RNAs were prepared at the indicated times after induction and subjected to real-time PCR using primers specific for SENP1 () and SENP2 (f).
The mRNA levels seen immediately after DMI treatment were set to 1.0, and the others are expressed as relative values. Data represent the
means	 the standard errors of the means of three independent experiments. (B) 3T3-L1 preadipocytes were incubated with DMI for the indicated
periods. After incubation, total RNAs were prepared and subjected to real-time PCR (left panel) or Northern blot analysis (right panel). A specific
probe for ribosomal protein s2 (RPS2) was used as an internal control in Northern blot analysis. (C) After incubation with DMI for the indicated
periods, cell lysates were prepared and subjected to immunoblot analysis. (D) Cells were incubated with IBMX, Dex, or insulin for the indicated
periods. (E) Cells were incubated for 8 h with IBMX in the absence or presence of H89 (10 or 50 M). RNAs were then prepared. (F) Cells were
incubated with or without forskolin (10 or 50 M) for 8 h.
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scription start site, mutations were inserted into this region
(i.e., replacement of ACG with GTT). This mutation abro-
gated the increase in Luc activity caused by forskolin and also
led to a significant decrease in basal transcription activity (Fig.
2A, lower panel). These results indicate that the SENP2 pro-
moter has a functional CRE. To confirm this finding, we per-
formed an EMSA by using a radiolabeled oligonucleotide
probe (wt) with the bp 113 to 81 sequence of the SENP2
promoter (Fig. 2B, upper panel). A slow-migrating band ap-
peared upon incubation of the probe with the nuclear extracts
prepared from 3T3-L1 preadipocytes that had not been treated
with DMI (Fig. 2B, lane 2 in lower panel). Significantly, the
binding activity was dramatically increased upon incubation
with the extract prepared 8 h after inducer treatment (lane 3).
Furthermore, supplementation with antibody against CREB
led to the appearance of a supershifted band (lane 4), and
unlabeled wild-type oligomers, but not mutated oligomers,
competed for the binding of CREB to the radiolabeled probe
in a dose-dependent fashion (lanes 5 to 9). These results indi-
cate that CREB binds to the probe and PKA activation is
involved in the binding of CREB to the SENP2 promoter. In
addition, a ChIP analysis was performed with anti-CREB an-
tibody and 3T3-L1 cells left untreated (control) or treated with
IBMX or DMI. CREB binding to the endogenous SENP2
promoter region (184/4 bp) was dramatically increased af-
ter the treatment of cells with IBMX or DMI (Fig. 2C). Col-
lectively, these results indicate that an elevated cAMP level
induces SENP2 expression through CREB binding to a func-
tional CRE in the SENP2 promoter.
SENP2 is required for adipocyte differentiation. Our finding
that SENP2 mRNA expression dramatically increases at the
early stage of adipocyte differentiation implies an important
role for SENP2 in adipogenesis. To test this possibility, 3T3-L1
preadipocytes were transfected with a SENP2-specific siRNA
(referred to as siSENP2) or a nonspecific control siRNA
(siNS) 1 day before DMI treatment. Transfection of siSENP2
caused a dramatic reduction in the SENP2 mRNA level at the
indicated times after DMI treatment (Fig. 3A). We then ex-
amined the effect of SENP2 mRNA knockdown on adipocyte
differentiation by transfection of siSENP2. Oil-red O staining
of lipid droplets in cells reveals that knockdown of SENP2
mRNA strongly attenuates adipocyte differentiation (Fig. 3B).
To rule out the possibility of an off-target effect of the siRNA
treatment, we tested four different types of siSENP2, and all of
the siSENP2 types tested significantly reduced SENP2 mRNA
levels and inhibited adipocyte differentiation (data not shown).
To determine whether this effect is specific to SENP2, we
compared the effect of siSENP1 to that of siSENP2. Of the
SENP family members, SENP1 is evolutionarily most closely
related to SENP2 and both SENPs are, at least in part, local-
ized in the nucleus (1, 27, 44). The SENP1 mRNA level was
significantly reduced by the transfection of siSENP1 (Fig. 3C).
In contrast to siSENP2, siSENP1 had little or no effect on
adipocyte differentiation (Fig. 3D). In addition, adenovirus-
mediated overexpression of SENP2 in 3T3-L1 or 3T3-F442A
cells increased the adipogenesis of both cell lines (data not
shown). These results suggest that SENP2 specifically plays a
critical role in the control of adipocyte differentiation.
SENP2 is required for the expression of C/EBP and
PPAR. To explore the mechanism by which SENP2 controls
adipogenesis, we examined the effect of SENP2 mRNA knock-
down on the expression of mRNAs of adipogenic transcription
factors. Transfection of siSENP2 had little or no effect on the
transcript levels of C/EBP and C/EBP (Fig. 3E, upper pan-
els). In contrast, expression of PPAR and C/EBP mRNAs
was strongly attenuated by knockdown of SENP2 mRNA
FIG. 2. Identification of a CRE in the SENP2 promoter. (A) Serial deletions of the SENP2 promoter region were fused to the Luc reporter
gene, and the resulting constructs were transfected into 3T3-L1 preadipocytes with pCMV-gal. Cells were incubated with or without forskolin for
18 h and then assayed for Luc and -galactosidase. Luc activities were normalized to -galactosidase activity. The normalized activity seen with
the construct without deletion was set to 1.0, and the others are expressed as relative values. Data represent the means 	 the standard errors of
the means of six independent experiments. The dots indicate the mutations at bp 101 to 99 of the SENP2 promoter. A putative CRE sequence
is underlined. (B) An oligonucleotide probe (wt) with the bp 113 to 81 sequence of the SENP2 promoter and a mutant form (mt) with GTT
in place of ACG (indicated by dots) were synthesized. Nuclear extracts were prepared from 3T3-L1 cells that had been incubated for 8 h with or
without DMI. For competition assays, the unlabeled probe (wt) or the mutant form (mt) was also included at 10- and 50-fold molar excesses over
the radiolabeled probe. In lane 1, the radiolabeled probe only was loaded. (C) 3T3-L1 cells were incubated in the absence (control [Con]) or
presence of IBMX or DMI for 8 h. They were then subjected to ChIP analysis by using anti-CREB antibody or control IgG as described in
Materials and Methods.
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(lower panels). We then examined the effect of siSENP2 on the
protein levels of the transcription factors. Immunoblot analysis
reveals that transfection of siSENP2 leads to a dramatic re-
duction in the protein levels of C/EBP and PPAR (Fig. 3F),
consistent with the siSENP2 effects on their transcript levels. In
addition, siSENP2 transfection resulted in a marked decrease
in both the transcript and protein levels of aP2 (data not
shown). On the other hand, siSENP2 did not have any effect on
FIG. 3. Effect of SENP2 knockdown on adipocyte differentiation. (A) 3T3-L1 preadipocytes were transfected with siSENP2 (50 nM) or siNS
(50 nM, nonspecific siRNA used as a negative control) 1 day before the induction of differentiation. Cells were incubated in differentiation medium
for the indicated periods. After incubation, aliquots (10 g) of total RNAs were subjected to Northern blot analysis with a SENP2 probe. (B) Cells
were stained with Oil Red O at the indicated times after DMI stimulation. (C) Total RNAs were isolated from cells at the indicated times after
DMI stimulation and then subjected to real-time PCR using primers specific for SENP1. The SENP1 mRNA level seen in the siNS-treated cells
immediately after DMI treatment was set to 1.0, and the others are expressed as relative values. Data represent the means 	 the standard errors
of the means of three independent experiments. (D) Cells transfected with siNS, siSENP1, or siSENP2 were stained with Oil Red O 8 days after
DMI treatment. (E) Total RNAs were prepared from cells transfected with siNS or siSENP2 at the indicated times after stimulation with DMI
and subjected to real-time PCR using primers specific for C/EBP, C/EBP, C/EBP, and PPAR. The mRNA level seen in siNS-transfected cells
immediately after DMI treatment was set to 1.0, and the others are expressed as relative values. Data represent the means 	 the standard errors
of the means of three independent experiments. (F) Cell lysates were obtained at the indicated times (days) after stimulation with DMI.
Immunoblot analysis was then performed using the respective antibodies. Nearly identical results were obtained in at least three independent
experiments. (G) Cells transfected with siNS or siSENP2 were incubated with DMI. Nuclear proteins were prepared at the indicated times (days)
after stimulation with DMI and subjected to EMSA with a labeled probe containing the C/EBP binding site of the C/EBP promoter. Antibodies
(2 g) against C/EBP and C/EBP were used for supershifting.
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the C/EBP protein level, similar to its lack of effect on the
C/EBP mRNA level. Notably, knockdown of SENP2 caused a
marked decrease in the C/EBP protein level, unlike its effect
on the C/EBP mRNA level. These results suggest that the
decrease in the C/EBP protein level caused by SENP2 knock-
down is due to a posttranslational modification that affects the
stability of the C/EBP protein.
To make clear that treatment of siSENP2 causes a defect in
the expression of C/EBP and PPAR through reduction of
the C/EBP protein level, an EMSA was performed with a
probe representing a C/EBP binding site in the C/EBP pro-
moter and nuclear extracts prepared 1 or 2 days after DMI
treatment. In accord with previous reports by other researchers
(22, 37), C/EBP binding was detectable at day 1 and dramat-
ically increased at day 2 in control siRNA (siNS)-treated cells
(Fig. 3G, lanes 3 to 4). However, in the case of siSENP2-
treated cells, binding activity was markedly reduced (lanes 5 to
6). The result obtained from the supershift with anti-C/EBP
antibody indicates that C/EBP is a major protein that binds to
the probe (lanes 7 and 8). Similar results were obtained when
a C/EBP binding site in the PPAR promoter was used as a
probe (data not shown). These results clearly showed that the
reduction of the C/EBP protein level by siSENP2 led to
attenuation of the expression of downstream target genes such
as those for C/EBP and PPAR. Collectively, these findings
suggest that SENP2 is required for C/EBP stabilization and
thereby for the expression of C/EBP and PPAR.
C/EBP is a substrate of SENP2. As C/EBP is a target for
sumoylation (10, 20), we determined whether SENP2 can de-
sumoylate C/EBP. SUMO1 and C/EBP were expressed in
COS-7 cells with or without Flag-tagged SENP2 and its cata-
lytically inactive mutant forms in which active-site Cys548 was
replaced with Ser (termed C548S) and Arg576 and Lys577
were replaced with Leu and Met, respectively (termed RK576/
577LM) (7, 19). As a control, Myc-SENP1 or Flag-SENP3 was
also expressed in place of SENP2. SENP2 could remove
SUMO1 from SUMO-C/EBP conjugates (Fig. 4A). On the
other hand, the catalytically inactive mutant SENP2 proteins
(C548S and RK576/577LM), SENP1, and SENP3 could not
desumoylate C/EBP. These results suggest that C/EBP is a
specific substrate for SENP2.
Next we examined the effect of SENP2 knockdown on the
level of endogenous SUMO-C/EBP conjugates. 3T3-L1 cells
transfected with increasing amounts of siSENP2 were incu-
bated with DMI for 24 h. Cell lysates were then subjected to
immunoprecipitation with anti-SUMO1 antibody, followed by im-
munoblotting with anti-C/EBP antibody. Little or no sumoy-
lated C/EBP could be detected when siNS was transfected (Fig.
4B). Upon siSENP2 transfection, however, SUMO-C/EBP con-
jugates were evidently accumulated. These results indicate that
endogenous SENP2 rapidly removes SUMO from C/EBP.
To determine whether desumoylation of C/EBP by SENP2
affects C/EBP transcriptional activity, COS-7 cells were trans-
fected with C/EBP and SENP2 expression vectors and the
p21 promoter (containing a C/EBP binding site)-Luc reporter
vector. As the amount of the SENP2 expression vector was
increased, the transcriptional activity of C/EBP was also in-
creased (Fig. 4C). In contrast, C548S mutant SENP2 did not
affect C/EBP transcriptional activity, suggesting that des-
umoylation of C/EBP increases its transcriptional activity.
SENP2 stabilizes the C/EBP protein. Our findings that
SENP2 knockdown leads to a marked decrease in the C/EBP
protein level with relatively little effect on its transcript level
and that C/EBP is a substrate of SENP2 suggested that
SENP2 is involved in the control of C/EBP protein stability.
To verify this possibility, HA-C/EBP and SUMO1 were ex-
pressed in COS-7 cells with Flag-SENP2 or Flag-C548S. Im-
munoblot analysis revealed that the level of C/EBP protein
increased in parallel with the increase in the expression of
SENP2 but not with that of catalytically inactive C548S (Fig.
4D). These results indicate that sumoylation causes destabili-
zation of the C/EBP protein and that this process can be
reversed by SENP2.
To determine whether sumoylation indeed affects the stabil-
ity of C/EBP, we examined the stability of sumoylated
C/EBP and nonsumoylated C/EBP in the presence of cyclo-
heximide, a protein synthesis inhibitor. Sumoylated C/EBP
was degraded more rapidly than the nonsumoylated form (Fig.
4E). Next, we generated a mutant form of C/EBP by replac-
ing Lys133, the SUMO acceptor site, with Arg (termed
K133R) (20). We then compared the stability of the sumoyla-
tion-defective K133R mutant protein to that of wild-type
C/EBP upon treatment with cycloheximide. Figure 4F shows
that the K133R mutant protein is more stable than C/EBP,
indicating that sumoylation is responsible for C/EBP desta-
bilization. To confirm this finding further, we examined the
effect of SENP2 knockdown on the stability of endogenous
C/EBP during the differentiation of 3T3-L1 cells. Cells trans-
fected with siNS or siSENP2 were incubated with cyclohexi-
mide 1 day after DMI treatment, when the C/EBP protein
level was high. Transfection of siSENP2, but not that of siNS,
into 3T3-L1 cells resulted in a marked decrease in the stability
of C/EBP (Fig. 4G). Taken together, these results indicate
that SENP2 plays a critical role in the control of C/EBP
protein stability.
Sumoylation of C/EBP promotes its ubiquitination. Hat-
tori et al. (15) have shown that C/EBP is degraded by the
ubiquitin-proteasome system. To determine whether sumoyla-
tion affects the ubiquitination of C/EBP and thereby its deg-
radation by the proteasome, COS-7 cells that had been trans-
fected with vectors expressing Ub and HA-tagged C/EBP or
K133R were incubated with or without MG132, a specific in-
hibitor of the proteasome. Without MG132 treatment, ubiq-
uitinated C/EBP was hardly detected whether SUMO1 was
coexpressed or not (Fig. 5A). In the presence of MG132, how-
ever, coexpression of SUMO1 led to a dramatic increase in the
level of ubiquitinated C/EBP, in addition to the generation of
sumoylated C/EBP. In contrast, ubiquitination of K133R was
hardly observed under any of the conditions described above.
In the same context, another sumoylation-defective mutant
form of C/EBP was generated (E135A) in which the Glu
residue in the sumoylation consensus site was replaced with
Ala (Fig. 5B). Similar to the K133R mutant form, ubiquitina-
tion of C/EBP E135A was hardly detected. These results
indicate that sumoylation promotes ubiquitination of C/EBP
and its subsequent degradation by the proteasome.
We next examined the effect of SENP2 overexpression on
C/EBP ubiquitination. Under conditions in which SUMO1
was coexpressed, SENP2 expression caused a marked reduc-
tion in the level of ubiquitinated C/EBP concomitantly with
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the disappearance of sumoylated C/EBP (Fig. 5C). When
SENP2 was not overexpressed, high-molecular-weight bands,
considered to be ubiquitinated C/EBP-SUMO conjugates,
were also detected with an anti-SUMO antibody after a longer
exposure. On the other hand, SENP2 overexpression had little
or no effect on the level of ubiquitinated proteins in the whole-
cell lysates, indicating that SENP2 does not modulate the ubiq-
uitination system itself. We then examined the effect of SENP2
FIG. 4. C/EBP is a substrate of and is stabilized by SENP2. (A) COS-7 cells were transfected with expression vectors for C/EBP and
SUMO-1 and a SENP expression vector (Myc-SENP1 or Flag-tagged SENP2, SENP3, RK576/577LM, or C548S). They were then subjected to
immunoblotting with anti-C/EBP, anti-Myc, or anti-Flag antibody. (B) 3T3-L1 cells transfected with siNS (100 nM) or siSENP2 (50 or 100 nM)
were incubated with DMI for 24 h. They were then subjected to immunoprecipitation (IP) with anti-SUMO1 antibody, followed by immunoblotting
(IB) with anti-C/EBP antibody. Cell lysates were also directly probed with the respective antibodies. (C) COS-7 cells were transfected with the
expression vectors for C/EBP (0.02 g), SENP2 (0.02, 0.05, or 0.1 g), or SENP2 C548S (0.1 g), the p21 promoter-Luc reporter vector (0.2 g),
and pCMV--gal (0.1 g). The normalized activity seen without C/EBP or SENP2 was set to 1.0, and the others are expressed as relative values.
Data represent the means 	 the standard errors of the means of five independent experiments. (D) COS-7 cells transfected with the expression
vectors for HA-C/EBP (0.25 g), SUMO1 (1 g), and Flag-SENP2 (0.25, 0.5, or 1 g) or Flag-C548S (0.25, 0.5, or 1 g) were incubated for 40 h.
Cell lysates were then subjected to immunoblot analysis. (E) COS-7 cells transfected with the expression vectors for SUMO1 and HA-C/EBP were
incubated with cycloheximide (5 M) for the indicated periods. After incubation, cell lysates were subjected to immunoblot analysis with
anti-C/EBP or anti--actin antibody. The densities of the C/EBP and C/EBP-SUMO bands seen immediately after cycloheximide treatment
were set to 100%, and the others are expressed as relative values. Data represent the means	 the standard errors of the means of four independent
experiments. (F) COS-7 cells transfected with the expression vectors for SUMO1 and HA-C/EBP or HA-K133R were incubated with cyclohex-
imide (5 M) for the indicated periods. Data represent the means 	 the standard errors of the means of four independent experiments.
(G) 3T3-L1 cells transfected with siSENP2 or siNS were treated with DMI for 24 h and then incubated with cycloheximide for the indicated
periods. Data represent the means 	 the standard errors of the means of four independent experiments. , P  0.05. K, 103.
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knockdown on the ubiquitination of endogenous C/EBP.
3T3-L1 preadipocytes transfected with siSENP2 or siNS were
induced with DMI for 24 h. Cells were then incubated with or
without MG132 and subjected to immunoprecipitation with
anti-C/EBP antibody. Without MG132 treatment, ubiquiti-
nated C/EBP was hardly detected whether siSENP2 or siNS
was transfected (Fig. 5D). In the presence of MG132, however,
the level of ubiquitinated C/EBP in cells transfected with
siSENP2 was much higher than in cells transfected with siNS.
On the other hand, neither siSENP2 nor siNS had any effect on
the level of ubiquitinated proteins in the whole-cell lysates,
again indicating that SENP2 does not modulate the ubiquiti-
nation system itself. Collectively, these results demonstrate
that SENP2 stabilizes the C/EBP protein.
C/EBP overexpression reverses siSENP2-mediated inhibi-
tion of adipogenesis. To determine whether SENP2-mediated
stabilization of C/EBP is associated with adipocyte differen-
tiation, we generated 3T3-L1 preadipocytes that stably over-
express C/EBP by using a retrovirus harboring a C/EBP
expression vector (pC/EBP). We also generated control cells
by infecting a retrovirus harboring an empty vector (pBabe).
Northern and immunoblot analyses confirm that C/EBP
mRNA and its protein product were highly expressed in the
stable cells but not in the control cells (Fig. 6A). We then
FIG. 5. Sumoylation of C/EBP promotes its ubiquitination. (A) COS-7 cells were transfected with the expression vectors for HA-C/EBP,
HA-K133R, Flag-SUMO1, and Myc-Ub as indicated. After incubation with MG132 (10 M) for 4 h, cell lysates were subjected to immunopre-
cipitation (IP) with anti-HA antibody, followed by immunoblotting (IB) with anti-Myc or anti-SUMO1 antibody. (B) COS-7 cells were transfected
with the indicated vectors and treated with MG132 as described for panel A. (C) HA-C/EBP, Flag-SUMO1, and Myc-Ub were expressed in
COS-7 cells with or without Flag-SENP2. The asterisk indicates IgG bands. (D) 3T3-L1 preadipocytes transfected with siSENP2 or siNS were
treated with DMI for 24 h and then incubated for 20 h with or without MG132. Cell lysates were then subjected to immunoprecipitation with
anti-C/EBP antibody, followed by immunoblotting with anti-C/EBP or anti-Ub antibody. K, 103.
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examined the effect of C/EBP overexpression in the stable
cells on adipogenesis under conditions in which SENP2 was
knocked down. Oil Red O staining revealed that overexpres-
sion of C/EBP in the stable cells ameliorated the inhibitory
effect of SENP2 knockdown on DMI-induced adipogenesis
(Fig. 6B). Consistently, the level of C/EBP protein in the
stable cells, but not in the control cells, remained elevated even
after the knockdown of SENP2 (Fig. 6C, left). Moreover, ex-
pression of the adipogenic genes downstream of C/EBP, such
as C/EBP and PPAR, was induced in the C/EBP-express-
ing stable cells but not in the control cells under conditions
in which SENP2 was knocked down (Fig. 6C, right). These
results indicate that C/EBP overexpression could reverse
siSENP2-mediated inhibition of adipogenesis. To demonstrate
the significance of sumoylation of C/EBP further, we used DI
(Dex plus insulin) instead of DMI to treat cells, in which the
expression of endogenous C/EBP and SENP2 was barely
induced (45) (Fig. 1D). In control cells, adipocytes were hardly
observed 8 days after DI treatment (Fig. 6D). However, the
stable cells expressing wild-type C/EBP partially rescued the
impaired adipogenesis and the cells expressing K133R mutant
C/EBP underwent adipogenesis at a level similar to that of
DMI-treated cells. This result clearly shows that the sumoyla-
tion-defective mutant form of C/EBP overcomes the SENP2
deficiency-mediated inhibition of adipogenesis better than
wild-type C/EBP does.
SENP2 is required for adipogenesis in vivo. To verify
whether SENP2 plays an important role in adipogenesis in
vivo, we generated retrovirus-mediated stable 3T3-F442A
preadipocytes producing shRNAs against SENP2 (shSENP2)
in which shRNAs against SENP2 were continuously expressed
and SENP2 transcription was significantly knocked down
(data not shown). 3T3-F442A preadipocytes (shControl or
shSENP2) were implanted into mice. While control preadipo-
cytes were differentiated into adipocytes and formed fat pads 5
weeks after implantation, adipogenesis was significantly inhib-
ited in the SENP2 knockdown stable cells when they were
implanted into mice (Fig. 7A). In addition to H&E staining
FIG. 6. C/EBP overexpression reverses siSENP2-mediated inhibition of adipogenesis. (A) 3T3-L1 preadipocytes were infected with a
retrovirus harboring an empty vector (pBabe) or a C/EBP expression vector (pC/EBP). After selection of cells resistant to puromycin, total
RNAs and proteins were prepared and subjected to Northern blot and immunoblot analyses, respectively. (B) Stable cells were transfected with
siNS or siSENP2. They were stained with Oil Red O 8 days after DMI treatment. (C) Stable cells transfected with siNS or siSENP2 were incubated
with DMI. Cell lysates were prepared at the indicated times after DMI treatment and then subjected to immunoblotting with the respective
antibodies. (D) Control (pBabe), C/EBP-expressing (pC/EBP), and C/EBP K133R-expressing (pC/EBP K133R) stable cells were incubated
with DI or DMI for 2 days and stained with Oil Red O 8 days after treatment. K, 103.
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(Fig. 7A, left), perilipin, a lipid droplet scaffold protein, was
detected by immunohistochemistry analysis (Fig. 7A, right).
Consistent with the result of H&E staining, perilipin was
hardly detected when SENP2 was stably knocked down. These
results clearly demonstrated that SENP2 is required for adi-
pogenesis in vivo.
Next, we compared the level of SENP2 mRNA in obese
mice such as high-fat-diet-fed, ob/ob, and db/db mice to that in
control mice. Interestingly, the SENP2 transcript levels in
obese mice were significantly higher than those in normal mice
(Fig. 7B). These results imply a critical in vivo function for
SENP2 in the control of adipogenesis.
DISCUSSION
In the present study, we show that SENP2 plays an essential
role in adipogenesis. Based on these findings, we propose a
model for the role of SENP2 in the control of adipogenesis
(Fig. 7C). In preadipocytes, expression of C/EBP remains
uninduced without stimulation. Moreover, the basal C/EBP
protein level would also be kept low by sumoylation, which
promotes ubiquitination and subsequent degradation of
C/EBP by the proteasome. Upon stimulation, such as by
differentiation inducers, expression of SENP2, as well as of
C/EBP, is induced in a cAMP-dependent fashion. SENP2-
FIG. 7. SENP2 is required for adipogenesis in vivo. (A) shControl or stable SENP2 knocked-down 3T3-F442A preadipocytes (shSENP2) were
implanted into mice. Implanted cell pads were excised and stained with H&E (left panel) or subjected to immunohistochemistry analysis with
antiperilipin antibody (right panel) 5 weeks after implantation. Similar results were obtained with three (shControl) and five (shSENP2) mice.
(B) Total RNAs were prepared from white adipose tissues of normally fed (n  5) and high-fat-diet-fed (n  5) mice (left panel), normal
(C57BL/6J, n  5) and ob/ob (n  5) mice (middle panel), and normal (n  5) and db/db (n  5) mice (right panel). The SENP2 mRNA levels
in the samples were then estimated by using real-time PCR. The mean values obtained from the normal mice were set to 1.0, and the others are
expressed as relative values. Data represent means 	 standard errors. , P  0.05. (C) Proposed model of the role of SENP2 in adipogenesis.
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mediated desumoylation and stabilization of C/EBP protein
further increase its cellular level, leading to induction of
the downstream effectors of C/EBP, such as PPAR and
C/EBP, for adipocyte differentiation.
C/EBP is considered to be a key regulator of adipocyte
differentiation because C/EBP is responsible for the expres-
sion of its downstream transcription factors such as C/EBP
and PPAR, and furthermore, the activity of C/EBP is finely
regulated by posttranslational modifications such as phosphor-
ylation. During the first 2-day period of differentiation,
C/EBP is sequentially phosphorylated by MAPK, Cdk2, and
glycogen synthase kinase 3 (GSK3) to acquire their C/EBP
and PPAR promoter DNA-binding activities and thus to in-
duce the expression of the downstream effectors (22, 37). Al-
though the C/EBP transcript level was dramatically increased
within 1 to 2 h after the treatment of 3T3-L1 preadipocytes
with DMI and gradually declined thereafter (Fig. 1B), the
C/EBP protein level remained elevated at least for the fol-
lowing 2 days (Fig. 3F), in accord with previous reports (38).
Likewise, the level of SENP2 protein remained elevated at
least for 2 days after DMI treatment. Thus, it appears likely
that during the 2-day period, SENP2-mediated stabilization
allows C/EBP to perform a crucial role in adipogenesis.
The finding that SENP2, but not SENP1 or SENP3, could
desumoylate C/EBP, suggests that C/EBP is a specific sub-
strate for SENP2. Furthermore, expression of SENP2 is in-
duced by the PKA-mediated CREB activation at the early
stage of adipogenesis while SENP1 expression is not induced
during adipogenesis. These results indicate that each SENP
has its specific target and specific physiological function. In
addition, it seems likely that transcriptional regulations of
SUMO proteases are important links to their specific func-
tions.
Although our data showed that C/EBP is a target of
SENP2 during adipogenesis, SENP2 can act on several other
SUMO-conjugated proteins. Therefore, we cannot exclude the
possibility that SENP2 is simultaneously working in the control
of other adipogenic factors that are modified by SUMO. Note-
worthy, however, was the finding that expression of SENP2
mRNA is increased immediately following the induction of
C/EBP mRNA expression during the early period of adipo-
genesis (i.e., about 3 to 4 h after the treatment of 3T3-L1
preadipocytes with DMI). Furthermore, the SENP2 protein
level was quite low when the protein levels of transcription
factors that are downstream of C/EBP, such as C/EBP and
PPAR, reached a maximum (Fig. 3F). Thus, it appears likely
that C/EBP serves as a major target of SENP2 for the regu-
lation of adipogenesis in a specific time window.
SENP2 has been shown to participate in downregulation of
the Wnt/-catenin signaling pathway (18, 19). Overexpression
of SENP2 decreases the -catenin protein level, although the
direct target involved in this process has not been identified.
The -catenin level is gradually decreased during adipogenesis,
and this decrease appears to be required for adipogenesis
because a high level of -catenin induced by Wnt or GSK3
inhibitors efficiently inhibits adipogenesis (2, 35). Therefore, it
would be of interest to investigate whether SENP2 is also
involved in the downregulation of the Wnt signaling pathway
during adipogenesis. Anyhow, our data, specially obtained
from C/EBP stable cells, indicate that C/EBP is a major
target of SENP2 for the control of adipogenesis.
Another important finding of this study is elucidation of the
mechanism by which sumoylation regulates C/EBP activity:
sumoylation of C/EBP stimulates its ubiquitination and sub-
sequent degradation. This fact may explain why an endogenous
sumoylated form of C/EBP was hardly observed. There are
several examples of sumoylation-mediated ubiquitination, such
as PML, HIF-1, and PEA3 (6, 14, 40). SUMO-dependent
recruitment of ubiquitin ligases such as RNF4 and VHL in-
volves the ubiquitination of PML and HIF-1. Like other post-
translational modifications, the SUMO-dependent ubiquitina-
tion pathway may regulate the level of a target protein without
any changes in E3 ubiquitin ligase expression. In addition, the
number of ubiquitin E3 ligases required could be reduced if it
is possible that one E3 ligase targets several proteins on the
basis of their sumoylation status. We also briefly examined
ubiquitination sites of C/EBP. The result showed that N-
terminal half domain of C/EBP contains major ubiquitination
sites and there are more than two lysine residues involved in
ubiquitination, one between amino acids 23 and 112 and the
other between amino acids 113 and 150 (data not shown). If
the C/EBP-specific E3 ligase and the lysine residues ubiqui-
tinated are identified, the molecular mechanism of the connec-
tion between the sumoylation and ubiquitination of C/EBP
can be precisely studied. It will be also interesting to study
whether sumoylation regulates other C/EBP family members
by a similar mechanism.
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